ClinicalTrials.gg
CompletedNCT01512563MIRA-coverUpdated Mar 11, 2020

Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent

An interventional study of Biliary stent in Biliary Stricture and Malignant Neoplasms, sponsored by Taewoong Medical Co., Ltd.. Completed at 3 sites in Korea, Republic of. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-03-11.

Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
19 Years to 90 Years
Sex
All
01

Study summary

Paclitaxel covered metal biliary stent extents their patency rate comparing to the Common Covered Metallic Biliary Stent.

Read the detailed description

Paclitaxel covered metal biliary stent(Mira-Cover Biliary Stent) extents their patency rate comparing to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent.

02

Conditions studied

  • Biliary Stricture
  • Malignant Neoplasms

Browse trials for

Keywords

  • paclitaxel
  • drug eluting stent
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 106 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Taewoong Medical Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

First submitted before Taewoong Medical Co., Ltd. became part of Olympus Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who is inoperable and/or unresectable cases of pancreatic cancer and/or biliary cancer with mid or distal CBD invasion
  • Among patient of a.,Patient who previously had surgical biliary drainage of plastic stent have eligibility

Exclusion criteria

Exclusion Criteria:

  • Patient who have under 3 months
  • Patient who have severe of Liver or whole body
  • Patient who previously had surgical biliary drainage
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Paclitaxel ElutingCovered Metal Stent

    Device: Biliary stent

  • Active comparator
    Covered Metal Stent

    Device: Biliary stent

Interventions

  • DeviceBiliary stent

    palliative treatment for malignant patients

    Also known as: Niti-S Mira-Cover Biliary Stent, Niti-S Biliary Stent

06

What researchers measure

Primary outcomes

  1. Accumulative Patency Rate

    Time frame: 6 month

Secondary outcomes

  1. Accumulative Survival Rate

    Time frame: 6 months

  2. Complications

    Time frame: 6 months

  3. Possibility of Other Treatment after Obstruction

    Time frame: 6 months

07

Study locations

3 sites
  • Soon Chun Hyang University Hospital Cheonan
    Cheonan, Korea, Republic of
  • Catholic University of Daegu School of Medicine
    Daegu, Korea, Republic of
  • Kangnam Severance Hospital
    Seoul, 135-720, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2012
First posted
Jan 19, 2012
Start
Feb 2007
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Last update
Mar 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01512563
Responsible party
Sponsor
First posted
Jan 19, 2012
Start date
Feb 2007
Primary completion
Feb 2010
Completion
Feb 2010
Last update
Mar 11, 2020

Study contacts

Dong Ki Lee, Ph.D
study chair · Kangnam Severance Hospital
Ho Gak Kim
principal investigator · Catholic University of Daegu School of Medicine
Sang Heum Park
principal investigator · Soon Chun Hyang University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion